Phone: 1.510.856.5600|info@anthera.com

Press Releases

 
Press Releases
  Date Title and Summary View
Jan 15, 2008
SAN MATEO, CA – January 15, 2008 – Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported preliminary results of a second Phase IIb clinical trial of A-002, for the treatment of cardiovascular disease. In this second study, administration of once-daily A-002 lowered both ...
Jan 8, 2008
SAN MATEO, CA – January 8, 2008 – Anthera Pharmaceuticals, Inc., a privately-held drug development company, announced today that it has entered into a license agreement with Amgen Inc. for the exclusive and worldwide rights to develop and commercialize AMG 623, a peptide fusion protein, for the treatment of systemic lup...
Dec 18, 2007
SAN MATEO, CA – December 18, 2007 – Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted A-001 orphan drug status for the prevention of acute chest...
Dec 6, 2007
SAN MATEO, CA - December 6, 2007 - Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, announced today the appointment of Christopher P. Lowe to the position of Vice President of Administration and Chief Financial Officer. Mr. Lowe will be r...
Oct 30, 2007
SAN MATEO, CA - October 30, 2007 - Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, today announced that Donald J. Santel has been appointed to Anthera’s Board of Directors. “Don’s experience in transfor...
Oct 24, 2007
SAN MATEO, CA - October 24, 2007 - Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported results of a Phase II clinical trial of its first compound, A-002, for the treatment of cardiovascular disease. The trial results suggest that treatment with A-002 resulted in significant reductions in blood lev...
Oct 3, 2007
SAN FRANCISCO‚ CA – October 3‚ 2007 – Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing anti-inflammatory therapeutics for chronic and acute inflammatory diseases, announced today the completion of enrollment and patient dosing in its Phase II clinical study of its lead com...
Jul 2, 2007
SAN MATEO, CA - July 2, 2007 - Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, announced today that enrollment of 200 patients in the phase 2 PLASMA (Phospholipase Levels And Serological Markers of Ath...
Apr 13, 2007
SAN MATEO, CA - April 13, 2007 - Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, announced today that enrollment has begun in the company's multi-center phase 2 clinical trial (PLASMA - Phospholipase Levels A...
Mar 20, 2007
San Mateo‚ CA – March 20‚ 2007 – Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, announced today the appointment of James E. Pennington, M.D. to the position of Executive Vice President & Chief Medical Officer. Dr...
Page: FirstPrevious ...
18
NextLast
= add release to Briefcase
Print Friendly